Discovery & Early Development Services

KCAS Bio is poised to perform bioanalytical drug discovery including assessment of a compound’s physiochemical properties, metabolite screening, bioavailability, toxicity and pharmacokinetics. KCAS Bio brings the full power of LBA and LC-MS/MS to your Drug Discovery and early stage research projects.

Talk to an expert

Rapid, rigorous drug discovery services

KCAS Bio organizes teams around early-stage rapid method development and analysis, as well as regulated preclinical and clinical phases, with support offered through NDA submission. We help with study design and perform the TK assessment once the bioanalytical data are available.

Our people

Tell us how we can help with your project

We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.

Talk to an expert

Related services

Ligand Binding Assays: a Plethora of Technologies to Address Your Projects’ Requirements Blogs
Read article Ligand Binding Assays: a Plethora of Technologies to Address Your Projects’ Requirements

Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the…

KCAS is Expanding Cutting-Edge Flow Services into Europe – What Does This Mean for You and Your International Projects? Blogs
Read article KCAS is Expanding Cutting-Edge Flow Services into Europe – What Does This Mean for You and Your International Projects?

In an exciting development, KCAS, through its subsidiary FlowMetric, is expanding its flow services in Europe. With a history of providing cutting-edge flow services in the EU, KCAS is taking a significant step forward by transitioning services from its Milan, Italy site to…

Recent FDA Guidance for Pharmacokinetics and Antibody Drug Conjugates, and What They Mean for Your Projects at KCAS Blogs
Read article Recent FDA Guidance for Pharmacokinetics and Antibody Drug Conjugates, and What They Mean for Your Projects at KCAS

With recent guidance released from the FDA, there are changes for PKs (Pharmacokinetics) and ADCs (Antibody Drug Conjugates) that must be clearly understood before making decisions for your drug product testing. ADCs combine the target specificity of monoclonal antibodies with the…

Agile, responsive, and easy to work with

We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.

Explore services